Liver Care for Frontline Clinicians (LIVE)

Create Account

Availability

Registration Closed

Sheraton Denver

Nov 07, 2026 8:00 AM - 4:00 PM MST

Cost

$0.00

Credit Offered

7 AMA PRA Category 1 Credits

Description
Learning Objectives
Accreditation Information
Faculty and Disclosures

Patients at risk for liver disease often have comorbidities such as type 2 diabetes, obesity, cardiovascular disease, alcohol use disorder, hypertension, and kidney disease. By addressing the underlying liver condition across the continuum of care, you can directly improve the patient’s overall health and positively impact these associated conditions.

Upon completion of this activity, participants should be able to:

Apply principles of primary and secondary prevention to screen for, diagnose, and manage patients with liver disease in primary care settings.
Interpret and utilize noninvasive diagnostic tools, including laboratory tests and elastography, to assess liver disease and guide treatment and referral decisions.
Implement evidence-based management and surveillance protocols for chronic liver diseases. Incorporate behavioral and pharmacologic strategies for steatotic liver disease into routine care to improve liver health.
Integrate practical workflow solutions and multidisciplinary collaboration into clinical practice to support sustainable, patient-centered liver health care delivery.

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for Integrity and Independence in Accredited Continuing Education. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content. 

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PLANNING COMMITTEE:
Ashley Kell, DNP
No relevant financial relationships

Christie Esquivel, MSPAS, PA-C
No relevant financial relationships

Hazel Domingo, MS
Employee: Gilead

Jimyeong Son, AGPCNP-BC
Scientific Consultant/Advisor: GlaxoSmithKline, Mirum

Jeanne Clark, MD, MPH
Consultant/Advisor: Boehringer Ingelheim, Novo Nordisk

Juan Pablo Arab, MD, FRCPC
No relevant financial relationships

Mazen Noureddin, MD, , MHSc, FAASLD
Scientific Consultant/Advisor: Akero, Altimmune, AstraZeneca, Boehringer Ingelheim, Boston Pharma, Corcept, Curve Biosciences, Calimetri, Daiichi Sankyo, Echosens, Enveda, Genentech,GSK, HepaNova, HepaTx, HistoIndex, Kriya, Lilly, Madrigal, Merck, Neuraly, Novo Nordisk, OPKO, Perspectum, Prometheus, Polykleitos, Regeneron, Rivus, Resolution Therapeutics
Stocks-Publicly Traded: Altimmune Inc, OPKO
Principal Investigator: Allergan, Altimmune, Akero, BI, BMS, Boston Pharma, Conatus, Corcept, Gilead, Galectin, Genfit, GSK, Kowa, Enanta, Madrigal, Lilly, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking and Zydus, GZBP, MALO
Speakers Bureau: Madrigal, Boehringer Ingelheim, Novo Nordisk
Media/Podcast: WebMD

Mia Lozada, MD
No relevant financial relationships

Norah Terrault, MD, MPH, FAASLD
Grant/Research Support: ImmunoCore, GlaxoSmithKline, Durect Corp, ImmunoCore, Genentech-Roche, Eiger Pharmaceuticals, Helio Health, GlaxoSmithKline
Leadership in Related Societies: HBV Foundation, Hepatitis B Foundation
Royalties: Elsevier

Paul Yien Kwo, MD, FAASLD
Scientific Consultant/Advisor: Gilead, Abbvie, Aligo, Novo Nordisk, Surrozen, Inventiva, Galapagos, Hepquant, Eiger, PPD, CDA Foundation, Ocelot, Arbutus, Ausper Bio, Amgen, Salix, Genentech, GlaxoSmithKline
Data Safety Monitoring Board: Aligos, Precision Biosciences, Lygenesis, Mirum, Tune Therapeutics
Grant/Research Support: Gilead, Janssen, Eiger, Altimmune, Durect, Ultragenyx, Madrigal, Fractyl, Ausper Bio, Salix, Takeda, Novo Nordisk, Vir Bio, Akero, 89Bio
Speaking/Teaching: Ipsen
Leadership in Related Society: Ipsen

Shraddha Batra, PA-C
No relevant financial relationships

W. Ray Kim, MD, FAASLD
No relevant financial relationships

FACULTY:
Alina M. Allen, MD
Scientific Consultant/Advisor: Novo Nordisk, Madrigal, Boehringer Ingelheim, 89bio, GlaxoSmithKline
Grant/Research Support: Target Pharma, Escopics, Oncoustics, Novo Nordisk, Madrigal, Boehringer Ingelheim, Siemens

Ani Kardashian, MD
No relevant financial relationships

Aparna Goel, MD
Scientific Consultant/Advisor: Amgen, Gilead, Mirum, Kezar Life Sciences, Intercept, Ipsen

Ashley Kell, DNP
No relevant financial relationships

Christie Esquivel, MSPAS, PA-C
No relevant financial relationships

Elizabeth S Aby, MD
No relevant financial relationships

Elliot B. Tapper, MD, FAASLD
Scientific Consultant/Advisor: Kaleido, Takeda, Ipsen, Tortugas, Madrigal, Resolution Therapeutics Satellite Bio, Gilead
Grant/Research Support: Ambys, Madrigal, Valeant, Novo Nordisk
Leadership in Related Society: AGA, Liver/Biliary Nominating Committee, Research Advisory Council

Gene Y. Im, MD, FAASLD
Scientific Consultant/Advisor: Korro Bio, Surrozen, Novo Nordisk, Alimentiv
Grant/Research Support: Echosens

Grace L. Su, MD, FAASLD
No relevant financial relationships

Hazel Domingo, MS
Employee: Gilead

Jimyeong Son, AGPCNP-BC
Scientific Consultant/Advisor: GlaxoSmithKline, Mirum

Juan Pablo Arab, MD, FRCPC
No relevant financial relationships

Marlyn J. Mayo, MD, FAASLD
Scientific Consultant/Advisor: Kezar, Mirum, Intercept, Ipsen, Zydus
Grant/Research Support: Gilead, Mirum, Ipsen, GlaxoSmithKline

Mazen Noureddin, MD, MHSc, FAASLD
Scientific Consultant/Advisor: Akero, Altimmune, AstraZeneca, Boehringer Ingelheim, Boston Pharma, Corcept, Curve Biosciences, Calimetri, Daiichi Sankyo, Echosens, Enveda, Genentech,GSK, HepaNova, HepaTx, HistoIndex, Kriya, Lilly, Madrigal, Merck, Neuraly, Novo Nordisk, OPKO, Perspectum, Prometheus, Polykleitos, Regeneron, Rivus, Resolution Therapeutics
Stocks-Publicly Traded: Altimmune Inc, OPKO
Principal Investigator: Allergan, Altimmune, Akero, BI, BMS, Boston Pharma, Conatus, Corcept, Gilead, Galectin, Genfit, GSK, Kowa, Enanta, Madrigal, Lilly, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking and Zydus, GZBP, MALO
Speakers Bureau: Madrigal, Boehringer Ingelheim, Novo Nordisk
Media/Podcast: WebMD

Meena B. Bansal, MD, FAASLD
Scientific Consultant/Advisor: Novo Nordisk, Madrigal, Boehringer Ingelheim, GlaxoSmithKline, Merck, Curve Bio, Boston Pharma, Eli Lilly, Petauri, Corcept, AstraZeneca, Echosens
Grant/Research Support: The Kinetix Group, NIH RO1, Pfizer, Histoindex, Siemens, Petauri
Data Safety Monitoring Board: TREAT Consortium, Surrozen

Mia Lozada, MD
No relevant financial relationships

Naim Alkhouri, MD, FAASLD
Consultant/Advisor: Madrigal, Ipsen, Gilead, Perspectum, Cima, 89Bio, Boehringer Ingelheim, Fibronostics, Novo Nordisk
Grant/Research Support: Merck, 89Bio, Arbutus, GlaxoSmithKline, Boston Pharma, Galectin, Gilead, Eli Lilly, Boehringer Ingelheim, Akero, Novo Nordisk, Pfizer
Speaking/Teaching: Echosens, Intercept

Paul Yien Kwo, MD, FAASLD
Scientific Consultant/Advisor: Gilead, Abbvie, Aligo, Novo Nordisk, Surrozen, Inventiva, Galapagos, Hepquant, Eiger, PPD, CDA Foundation, Ocelot, Arbutus, Ausper Bio, Amgen, Salix, Genentech, GlaxoSmithKline
Data Safety Monitoring Board: Aligos, Precision Biosciences, Lygenesis, Mirum, Tune Therapeutics
Grant/Research Support: Gilead, Janssen, Eiger, Altimmune, Durect, Ultragenyx, Madrigal, Fractyl, Ausper Bio, Salix, Takeda, Novo Nordisk, Vir Bio, Akero, 89Bio
Speaking/Teaching: Ipsen
Leadership in Related Society: Ipsen

Rohit Looma, MD, MHSc, FAASLD
Employee: LipoNexus
Scientific Consultant/Advisor: Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Bausch Health, Boehringer Ingelheim, Eccogene, Eli Lilly, GSK, HeptaBio, Inipharma, Insitro, Inventiva, Ionis, Kriya Therapeutics, Madrigal, Metavi, Novo Nordisk, Sagimet, Sourcebio, 89 bio, Roche, Takeda
Grant/Research Support: Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Eccogene, Eli Lilly, Gilead, GSK, Hanmi, HeptaBio, Inventiva, Ionis, Madrigal Pharmaceuticals, Novo Nordisk, Roche, TensorBio and Takeda

Shraddha Batra, PA-C
No relevant financial relationships

W. Ray Kim, MD, FAASLD
No relevant financial relationships

STAFF:
Steven Folstein, MFA M.Ed. 
No relevant financial relationships

Laura Shelters, MS Ed.
No relevant financial relationships

Roxanne Dobbs
No relevant financial relationships